HC Wainwright Issues Negative Outlook for Myomo Earnings

Myomo, Inc. (NYSEAMERICAN:MYO) – Stock analysts at HC Wainwright decreased their Q4 2025 earnings per share (EPS) estimates for shares of Myomo in a note issued to investors on Tuesday, November 11th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of ($0.08) per share for the quarter, down from their prior forecast of ($0.02). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at ($0.15) EPS and FY2028 earnings at $0.07 EPS.

Separately, Ascendiant Capital Markets cut their price objective on Myomo from $11.50 to $10.50 and set a “buy” rating for the company in a research report on Monday, September 22nd. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $7.83.

Myomo Price Performance

NYSEAMERICAN:MYO traded down $0.02 during trading hours on Thursday, hitting $0.83. 268,092 shares of the stock traded hands, compared to its average volume of 936,699. The company has a market cap of $31.79 million, a price-to-earnings ratio of -2.85 and a beta of 1.48. Myomo has a 1 year low of $0.79 and a 1 year high of $7.17. The stock has a 50 day moving average price of $0.97 and a 200 day moving average price of $1.93. The company has a quick ratio of 2.03, a current ratio of 2.49 and a debt-to-equity ratio of 0.17.

Insider Activity at Myomo

In related news, CEO Paul R. Gudonis acquired 50,000 shares of the stock in a transaction on Friday, August 15th. The shares were bought at an average price of $0.95 per share, with a total value of $47,500.00. Following the completion of the purchase, the chief executive officer owned 1,259,013 shares of the company’s stock, valued at approximately $1,196,062.35. This represents a 4.14% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Thomas F. Kirk bought 50,000 shares of Myomo stock in a transaction on Monday, August 25th. The shares were purchased at an average cost of $1.15 per share, for a total transaction of $57,500.00. Following the completion of the purchase, the director directly owned 474,420 shares of the company’s stock, valued at $545,583. This trade represents a 11.78% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders bought 150,000 shares of company stock worth $160,000. Company insiders own 4.79% of the company’s stock.

Institutional Trading of Myomo

Institutional investors have recently added to or reduced their stakes in the stock. Rosalind Advisors Inc. lifted its stake in Myomo by 33.0% during the second quarter. Rosalind Advisors Inc. now owns 3,595,788 shares of the company’s stock worth $7,767,000 after purchasing an additional 892,127 shares in the last quarter. AIGH Capital Management LLC boosted its stake in shares of Myomo by 22.3% in the second quarter. AIGH Capital Management LLC now owns 3,555,742 shares of the company’s stock valued at $7,680,000 after purchasing an additional 649,053 shares during the period. Geode Capital Management LLC increased its stake in Myomo by 160.8% during the 2nd quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock worth $1,446,000 after buying an additional 412,631 shares during the period. Stonepine Capital Management LLC lifted its holdings in Myomo by 65.3% during the 2nd quarter. Stonepine Capital Management LLC now owns 457,419 shares of the company’s stock worth $988,000 after buying an additional 180,712 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in Myomo by 84.2% in the 1st quarter. Jane Street Group LLC now owns 162,658 shares of the company’s stock valued at $782,000 after buying an additional 74,338 shares during the period. Institutional investors and hedge funds own 44.99% of the company’s stock.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.